HC Wainwright set a $50.00 price target on Opexa Therapeutics (NASDAQ:ACER) in a research note released on Thursday, January 4th. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Separately, ValuEngine cut shares of Opexa Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st.
Opexa Therapeutics (NASDAQ ACER) traded up $0.97 during mid-day trading on Thursday, reaching $19.50. 147,400 shares of the company’s stock were exchanged, compared to its average volume of 64,563. Opexa Therapeutics has a one year low of $5.69 and a one year high of $22.63. The company has a market capitalization of $138.92, a PE ratio of -4.84 and a beta of 2.23.
Opexa Therapeutics (NASDAQ:ACER) last released its earnings results on Monday, November 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter. research analysts predict that Opexa Therapeutics will post -1.48 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://ledgergazette.com/2018/01/12/opexa-therapeutics-acer-given-a-50-00-price-target-at-hc-wainwright.html.
About Opexa Therapeutics
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Opexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.